Android app on Google Play

Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis

May 21, 2012 12:29 PM EDT Send to a Friend
On May 16, 2012, Medicis Pharmaceutical Corporation (NYSE": MRX) received verbal notification that the United States Patent and Trademark Office expects to issue Notices of Allowance for the Company’s United States patent applications directed to the use of ZYCLARA for the treatment of actinic keratosis.

The patent applications are U.S. Application Nos. 13/179,315, entitled 2 x 2 x 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod, 13/181,499, entitled 2 x 2 x 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod, and 13/182,433, entitled Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream. As of May 18, 2012, the intended issuance of the Notices of Allowance was reflected on the USPTO’s public Patent Application Information Retrieval (PAIR) website. The Company expects to receive the formal Notices of Allowance from the USPTO in the second quarter of 2012.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment